Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

EXEL

Exelixis Inc

Feb 21 • 04:00PM ET

36.85

Dollar change +1.76
Percentage change 5.02	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VXF VBK XMHQ MDY XBI IJK IBB

Index	-	P/E	20.79	EPS (ttm)	1.77	Insider Own	2.79%	Shs Outstand	281.73M	Perf Week	6.84%
Market Cap	10.31B	Forward P/E	15.67	EPS next Y	2.35	Insider Trans	-5.37%	Shs Float	272.08M	Perf Month	12.07%
Income	521.27M	PEG	1.01	EPS next Q	0.38	Inst Own	90.53%	Short Float	4.81%	Perf Quarter	6.75%
Sales	2.17B	P/S	4.76	EPS this Y	14.97%	Inst Trans	1.33%	Short Ratio	5.69	Perf Half Y	39.16%
Book/sh	7.97	P/B	4.63	EPS next Y	16.21%	ROA	17.42%	Short Interest	13.09M	Perf Year	78.62%
Cash/sh	3.97	P/C	9.28	EPS next 5Y	20.54%	ROE	23.13%	52W Range	20.14 - 37.59	Perf YTD	10.66%
Dividend Est.	-	P/FCF	15.36	EPS past 5Y	11.55%	ROI	21.41%	52W High	-1.97%	Beta	0.60
Dividend TTM	-	Quick Ratio	3.58	Sales past 5Y	18.34%	Gross Margin	96.49%	52W Low	82.97%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	3.63	EPS Y/Y TTM	176.71%	Oper. Margin	31.81%	RSI (14)	65.59	Volatility	3.31% 3.23%
Employees	1147	Debt/Eq	0.10	Sales Y/Y TTM	18.49%	Profit Margin	24.04%	Recom	1.96	Target Price	37.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	74.38%	Payout	0.00%	Rel Volume	1.52	Prev Close	35.09
Sales Surprise	0.41%	EPS Surprise	12.81%	Sales Q/Q	18.16%	Earnings	Feb 11 AMC	Avg Volume	2.30M	Price	36.85
SMA20	9.47%	SMA50	7.56%	SMA200	30.42%	Trades		Volume	3,489,816	Change	5.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28
Nov-19-21	Initiated	Piper Sandler	Overweight	$34
Nov-03-21	Resumed	Jefferies	Buy	$28

Show Previous Ratings

Feb-21-25 06:31PM	Why Exelixis Stock Trounced the Market on Thursday (Motley Fool) +5.02%
01:30PM	Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? (Benzinga)
Feb-20-25 05:05PM	Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program (Business Wire)
12:45PM	Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-17-25 09:15AM	International Markets and Exelixis (EXEL): A Deep Dive for Investors (Zacks)
08:19AM	Loading…
08:19AM	Five-year results see Exelixis RCC therapy extending overall survival (Clinical Trials Arena)
Feb-15-25 11:10AM	Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX (cabozantinib) in Combination with Opdivo (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 (Business Wire)
Feb-14-25 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-13-25 04:05PM	Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit (Business Wire) +5.15%
Feb-12-25 02:13AM	Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-25 10:15PM	Exelixis (EXEL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates (Zacks)
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
09:00AM	Loading…
Feb-10-25 09:00AM	2 Stocks to Buy With Less Than $40 (Motley Fool)
Feb-07-25 05:00AM	The 10 best stocks of the last decade (Quartz)
Feb-06-25 09:15AM	Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Jan-29-25 09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-28-25 04:05PM	Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)
10:00AM	Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-25-25 10:00AM	Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 (Business Wire)
Jan-24-25 02:30PM	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025 (Business Wire) -5.13%
01:37PM	Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? (GuruFocus.com)
11:17AM	Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns (GuruFocus.com)
Jan-22-25 07:44AM	Revenues, Treatment Pipeline Driving Exelixis Higher (FX Empire) -9.74%
Jan-21-25 09:32AM	What Makes Exelixis (EXEL) an Investment Bet? (Insider Monkey)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
12:10PM	Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again (Zacks)
09:40AM	Loading…
Jan-13-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Jan-12-25 04:00PM	Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 (Business Wire)
Jan-09-25 09:00AM	Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Jan-06-25 04:05PM	Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (Business Wire)
Dec-31-24 06:20AM	Exelixis price target raised to $38 from $34 at RBC Capital (TipRanks)
Dec-23-24 10:23AM	Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-17-24 08:00AM	Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024 (PR Newswire)
Dec-09-24 12:45PM	Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-07-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in December (Motley Fool)
Nov-29-24 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-28-24 11:31AM	Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December (Business Wire)
Nov-26-24 04:05PM	Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Nov-25-24 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Exelixis (EXEL) (Zacks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily)
12:00PM	What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-07-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November (Business Wire)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Nov-05-24 12:45PM	Here is Why Growth Investors Should Buy Exelixis (EXEL) Now (Zacks)
12:20PM	Earnings Estimates Rising for Exelixis (EXEL): Will It Gain? (Zacks)
Nov-04-24 09:15AM	Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know (Zacks)
Nov-03-24 06:41AM	3 Magnificent Stocks Under $100 to Buy in November (Motley Fool)
Oct-31-24 07:00PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
07:29AM	Exelixis price target raised to $36 from $33 at Piper Sandler (TipRanks)
Oct-30-24 11:40AM	Q3 2024 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents) +12.91%
03:15AM	Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
02:51AM	Analyst Report: Exelixis, Inc. (Morningstar Research)
12:00AM	Exelixis (EXEL) Q3 2024 Earnings Call Transcript (Motley Fool)
Oct-29-24 06:30PM	Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Exelixis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-24-24 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-23-24 12:00PM	Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy (Zacks)
09:53AM	1 No-Brainer Stock to Buy With $40 (Motley Fool)
Oct-22-24 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-21-24 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Oct-16-24 11:01AM	Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-24 04:05PM	Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire) +8.61%
01:57PM	Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories (Business Wire)
07:39AM	Exelixis and MSD to trial cancer therapies together in clinical collaboration (Clinical Trials Arena)
Oct-14-24 08:00AM	Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma (Business Wire)
Oct-09-24 08:30AM	ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS (PR Newswire)
Sep-26-24 08:45AM	2 Growth Stocks to Buy With Less Than $100 (Motley Fool)
Sep-20-24 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Sep-16-24 09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
09:13AM	Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss (Pharmaceutical Technology)
08:45AM	Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine (Business Wire)
Sep-15-24 08:45AM	Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 (Business Wire)
Sep-14-24 07:39PM	Exelixis, Inc. (EXEL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-05-24 11:31AM	Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-02-24 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-29-24 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Aug-28-24 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September (Business Wire)
Aug-26-24 12:20PM	Why Exelixis (EXEL) Might be Well Poised for a Surge (Zacks)
Aug-17-24 01:01AM	Insider Sale: Director Maria Freire Sells 8,250 Shares of Exelixis Inc (EXEL) (GuruFocus.com)
Aug-16-24 08:09AM	Exelixis Earnings Drive Share Growth (FX Empire)
Aug-13-24 09:44AM	Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results (Zacks)
Aug-12-24 09:15AM	Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends (Zacks)
Aug-11-24 09:31PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
Aug-09-24 10:28AM	Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review (Investor's Business Daily)
07:35AM	Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now? (Insider Monkey)
Aug-07-24 02:29PM	Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors (Business Wire) +13.09%
01:30PM	Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues (Zacks)
07:46AM	FDA accepts Exelixis' cabozantinib sNDA for neuroendocrine tumours (Pharmaceutical Business Review)
01:15AM	Exelixis (EXEL) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-06-24 06:30PM	Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates (Zacks)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beckerle Mary C	Director	Feb 14 '25	Option Exercise	23.24	8,354	194,147	42,616	Feb 19 08:32 PM
Beckerle Mary C	Director	Feb 14 '25	Sale	34.88	12,210	425,878	30,406	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Option Exercise	20.50	15,874	325,417	184,894	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Sale	34.74	15,874	551,463	169,020	Feb 19 08:32 PM
Freire Maria C	Director	Feb 14 '25	Option Exercise	21.52	44,114	949,521	135,121	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Sale	34.94	44,114	1,541,343	91,007	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Option Exercise	23.24	7,712	179,227	41,974	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Sale	35.02	11,568	405,111	30,406	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Proposed Sale	34.94	44,114	1,541,207		Feb 14 05:59 PM
Beckerle Mary C	Director	Feb 14 '25	Proposed Sale	34.88	12,210	425,865		Feb 14 05:40 PM
POSTE GEORGE	Director	Feb 14 '25	Proposed Sale	34.74	15,874	551,431		Feb 14 05:36 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Proposed Sale	34.37	11,568	397,592		Feb 14 04:20 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Option Exercise	18.80	96,986	1,823,337	595,931	Nov 07 07:44 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Sale	35.00	96,986	3,394,510	498,945	Nov 07 07:44 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 01 '24	Sale	34.13	50,000	1,706,500	530,325	Nov 05 07:05 PM
POSTE GEORGE	Director	Nov 01 '24	Sale	34.00	30,000	1,020,000	169,020	Nov 05 07:04 PM
DANA T AFTAB	Officer	Nov 05 '24	Proposed Sale	35.00	96,986	3,394,510		Nov 05 04:23 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Oct 30 '24	Sale	31.40	1,162	36,487	498,945	Nov 01 06:43 PM
POSTE GEORGE	Director	Nov 01 '24	Proposed Sale	34.00	30,000	1,020,112		Nov 01 04:54 PM
JEFFREY J HESSEKIEL	Officer	Nov 01 '24	Proposed Sale	33.20	25,000	830,000		Nov 01 04:47 PM
Hessekiel Jeffrey	EVP & General Counsel	Oct 28 '24	Sale	28.39	25,000	709,750	580,325	Oct 30 06:04 PM
DANA T AFTAB	Officer	Oct 30 '24	Proposed Sale	31.40	1,162	36,487		Oct 30 04:10 PM
Haley Patrick J.	EVP, Commercial	Oct 02 '24	Option Exercise	24.41	100,000	2,441,000	441,036	Oct 03 09:22 PM
MORRISSEY MICHAEL	President and CEO	Oct 01 '24	Option Exercise	24.41	480,000	11,716,800	1,444,384	Oct 03 09:22 PM
Hessekiel Jeffrey	EVP & General Counsel	Sep 23 '24	Sale	26.38	25,000	659,500	605,325	Sep 25 07:32 PM
JEFFREY J HESSEKIEL	Officer	Sep 23 '24	Proposed Sale	26.42	75,000	1,981,500		Sep 23 04:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Option Exercise	24.41	20,000	488,200	650,325	Aug 28 07:07 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Sale	25.79	20,000	515,800	630,325	Aug 28 07:07 PM
Freire Maria C	Director	Aug 14 '24	Sale	26.56	8,250	219,120	91,007	Aug 16 07:35 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 12 '24	Sale	27.06	20,883	565,094	500,107	Aug 14 07:12 PM
MARIA C FREIRE	Director	Aug 14 '24	Proposed Sale	26.56	8,250	219,122		Aug 14 05:01 PM
POSTE GEORGE	Director	Aug 08 '24	Sale	26.89	33,725	906,865	199,020	Aug 12 07:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Option Exercise	24.41	95,000	2,318,950	615,990	Aug 09 07:32 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Sale	25.00	95,000	2,375,000	520,990	Aug 09 07:32 PM
Haley Patrick J.	EVP, Commercial	Aug 07 '24	Sale	25.50	14,000	357,000	341,036	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Option Exercise	24.41	80,000	1,952,800	710,325	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Sale	25.97	80,000	2,077,600	630,325	Aug 09 07:32 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Option Exercise	24.41	125,000	3,051,250	846,680	Aug 09 07:31 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Sale	27.19	125,000	3,398,750	721,680	Aug 09 07:31 PM
Senner Christopher J.	Officer	Aug 09 '24	Proposed Sale	27.17	125,000	3,396,250		Aug 09 05:20 PM
Aftab Dana	Officer	Aug 09 '24	Proposed Sale	27.25	20,883	569,062		Aug 09 05:18 PM
POSTE GEORGE	Director	Aug 08 '24	Proposed Sale	26.89	33,725	906,746		Aug 08 05:42 PM
DANA T AFTAB	Officer	Aug 07 '24	Proposed Sale	25.00	95,000	2,375,000		Aug 07 04:17 PM
JEFFREY J HESSEKIEL	Officer	Aug 07 '24	Proposed Sale	23.45	100,000	2,345,000		Aug 07 04:13 PM
PATRICK JOSEPH HALEY	Officer	Aug 07 '24	Proposed Sale	25.50	14,000	357,000		Aug 07 04:11 PM
WYSZOMIERSKI JACK L	Director	Jun 04 '24	Sale	22.00	8,287	182,314	349,499	Jun 06 08:37 PM
JOHNSON DAVID EDWARD	Director	May 30 '24	Buy	20.76	225,000	4,670,055	1,525,730	May 30 07:50 PM
JOHNSON DAVID EDWARD	Director	May 28 '24	Buy	20.32	200,000	4,063,900	1,300,730	May 30 07:50 PM
Smith Julie	Director	May 21 '24	Sale	21.12	27,280	576,154	5,445	May 23 06:55 PM
POSTE GEORGE	Director	May 21 '24	Option Exercise	19.57	11,686	228,695	225,593	May 22 07:23 PM
POSTE GEORGE	Director	May 21 '24	Sale	20.96	11,686	244,939	213,907	May 22 07:23 PM
PAPADOPOULOS STELIOS	Director	May 20 '24	Option Exercise	19.57	11,686	228,695	1,272,015	May 22 07:23 PM
PAPADOPOULOS STELIOS	Director	May 20 '24	Sale	21.00	11,437	240,177	1,260,578	May 22 07:23 PM
WYSZOMIERSKI JACK L	Director	May 13 '24	Option Exercise	19.57	11,686	228,695	349,871	May 15 07:44 PM
WYSZOMIERSKI JACK L	Director	May 13 '24	Sale	21.37	10,923	233,425	338,948	May 15 07:44 PM
Garber Alan M	Director	Mar 21 '24	Option Exercise	19.57	23,491	459,719	54,908	Mar 25 07:31 PM
Garber Alan M	Director	Mar 21 '24	Sale	24.01	19,205	461,112	35,703	Mar 25 07:31 PM

Open in Screener

HUN

Huntsman Corp

Feb 21 • 04:00PM ET

17.60

Dollar change -0.18
Percentage change -1.01	%

Basic Materials • Chemicals • USA • NYSE

Peers: DOW DD PPG EMN LYB AVNT FMC ALB IOSP ASH

| Held by: VTI SCHD VB DVY VBR VXF DFAT SCHA DES DFSV

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	6.00%	Shs Outstand	172.14M	Perf Week	3.65%
Market Cap	3.04B	Forward P/E	19.99	EPS next Y	0.88	Insider Trans	-0.19%	Shs Float	162.60M	Perf Month	0.69%
Income	-162.00M	PEG	-	EPS next Q	-0.08	Inst Own	86.52%	Short Float	3.24%	Perf Quarter	-9.60%
Sales	6.04B	P/S	0.50	EPS this Y	336.77%	Inst Trans	1.48%	Short Ratio	2.00	Perf Half Y	-15.18%
Book/sh	17.19	P/B	1.02	EPS next Y	364.90%	ROA	-2.26%	Short Interest	5.26M	Perf Year	-27.63%
Cash/sh	1.97	P/C	8.95	EPS next 5Y	-	ROE	-5.22%	52W Range	15.67 - 27.01	Perf YTD	-2.38%
Dividend Est.	1.01 (5.73%)	P/FCF	38.54	EPS past 5Y	-	ROI	-3.36%	52W High	-34.84%	Beta	0.98
Dividend TTM	1.00 (5.68%)	Quick Ratio	0.77	Sales past 5Y	-0.89%	Gross Margin	14.35%	52W Low	12.32%	ATR (14)	0.65
Dividend Ex-Date	Mar 14, 2025	Current Ratio	1.36	EPS Y/Y TTM	-277.52%	Oper. Margin	1.23%	RSI (14)	53.34	Volatility	5.63% 3.61%
Employees	6300	Debt/Eq	0.76	Sales Y/Y TTM	-1.23%	Profit Margin	-2.68%	Recom	2.35	Target Price	20.71
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	-77.47%	Payout	-	Rel Volume	0.89	Prev Close	17.78
Sales Surprise	0.56%	EPS Surprise	-159.34%	Sales Q/Q	3.49%	Earnings	Feb 17 AMC	Avg Volume	2.63M	Price	17.60
SMA20	2.71%	SMA50	0.01%	SMA200	-17.31%	Trades		Volume	2,334,043	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-15-25	Downgrade	Alembic Global Advisors	Overweight → Neutral
Jun-07-24	Upgrade	JP Morgan	Underweight → Overweight	$22 → $27
Feb-23-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $32
Dec-11-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28
Oct-18-23	Upgrade	BofA Securities	Underperform → Buy	$27
Jun-14-23	Initiated	Citigroup	Neutral	$27
Apr-12-23	Initiated	Mizuho	Neutral	$27
Feb-22-23	Downgrade	Vertical Research	Buy → Hold
Nov-08-22	Downgrade	Tudor, Pickering, Holt & Co.	Buy → Hold
Nov-07-22	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Oct-13-22	Initiated	Goldman	Sell	$26
Oct-13-22	Downgrade	Seaport Research Partners	Buy → Neutral
Sep-20-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $28
Sep-20-22	Downgrade	JP Morgan	Neutral → Underweight	$25
Sep-19-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$43 → $30
Sep-12-22	Initiated	Credit Suisse	Outperform	$33
Jul-25-22	Downgrade	UBS	Buy → Neutral	$40
Jun-14-22	Downgrade	BofA Securities	Buy → Underperform	$45 → $34
Mar-31-22	Resumed	BofA Securities	Buy	$46
Mar-21-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight

Show Previous Ratings

Feb-19-25 10:30AM	Huntsman to aggressively push for margin expansion in 2025, CEO says (TipRanks)
02:04AM	Huntsman Corp (HUN) Q4 2024 Earnings Call Highlights: Strategic Moves and Market Recovery (GuruFocus.com)
01:30AM	Q4 2024 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-18-25 04:00PM	Huntsman Announces First Quarter 2025 Common Dividend and 2025 Annual Meeting of Stockholders (PR Newswire)
05:07AM	Huntsman: Q4 Earnings Snapshot (Associated Press Finance)
02:41AM	Loading…
02:41AM	Huntsman Corp (HUN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-17-25 04:34PM	Huntsman Announces Fourth Quarter 2024 Earnings (PR Newswire)
Feb-14-25 09:44AM	How To Earn $500 A Month From Huntsman Stock Ahead Of Q4 Earnings (Benzinga)
07:12AM	Huntsman Corp (HUN) Q4 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Jan-31-25 06:08PM	Is Huntsman Corporation (HUN) Among the Best Chemical Stocks to Buy According to Analysts? (Insider Monkey)
Jan-26-25 09:00PM	Germanys Economic Model Is Broken, and No One Has a Plan B (The Wall Street Journal)
Jan-14-25 04:00PM	Huntsman to Discuss Fourth Quarter 2024 Results on February 18, 2025 (PR Newswire)
Jan-08-25 07:55AM	Huntsman price target lowered to $21 from $23 at Mizuho (TipRanks)
Dec-20-24 07:36AM	Huntsman price target lowered to $20 from $23 at RBC Capital (TipRanks)
Dec-18-24 08:38AM	Is the Options Market Predicting a Spike in Huntsman (HUN) Stock? (Zacks)
06:46AM	Loading…
Nov-07-24 06:46AM	Huntsman price target lowered to $25 from $26 at Wells Fargo (TipRanks)
Nov-06-24 03:50AM	Q3 2024 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Huntsman Corp (HUN) Q3 2024 Earnings Call Highlights: Strategic Cost Reductions and Market ... (GuruFocus.com)
Nov-05-24 04:00PM	Huntsman Announces Fourth Quarter 2024 Common Dividend (PR Newswire)
Nov-04-24 04:43PM	Huntsman: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Huntsman Announces Third Quarter 2024 Earnings (PR Newswire)
07:04AM	Earnings To Watch: Huntsman Corp (HUN) Reports Q3 2024 Result (GuruFocus.com)
Nov-01-24 09:02AM	Earnings To Watch: Huntsman Corp (HUN) Reports Q3 2024 Result (GuruFocus.com)
Oct-12-24 08:31AM	Huntsman price target raised to $24 from $21 at RBC Capital (TipRanks)
Oct-03-24 11:00AM	Huntsman to Discuss Third Quarter 2024 Results on November 5, 2024 (PR Newswire)
Oct-01-24 10:00AM	Huntsman Selects ISNetworld for Contractor Management (Business Wire)
Sep-24-24 05:15PM	Huntsman Prices $350 Million of Senior Notes (PR Newswire)
Sep-20-24 09:46AM	The competitiveness of AI will be both technically and energy-driven, says Peter Huntsman (CNBC TV)
Aug-21-24 08:06AM	Here's Why You Should Hold Onto Huntsman (HUN) Stock for Now (Zacks)
Aug-07-24 03:00AM	Q2 2024 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
10:31AM	Loading…
Aug-06-24 10:31AM	Huntsman's (HUN) Q2 Earnings Beat Estimates, Revenues Miss (Zacks)
Aug-05-24 05:32PM	Huntsman: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Huntsman Announces Second Quarter 2024 Earnings (PR Newswire)
06:00AM	Huntsman Announces Third Quarter 2024 Common Dividend (PR Newswire)
Aug-01-24 07:00AM	Jan Buberl Appointed President of Performance Products Division (PR Newswire)
Jul-10-24 04:59PM	Huntsman to Discuss Second Quarter 2024 Results on August 6, 2024 (PR Newswire)
Jul-04-24 07:22AM	Here's Why You Should Hold Onto Huntsman (HUN) Stock for Now (Zacks)
Jun-18-24 08:09AM	Huntsman (HUN) Gains on Downstream Expansion, Acquisitions (Zacks)
Jun-14-24 06:25AM	Huntsman (HUN) Unveils New Innovation Center in Belgium (Zacks)
Jun-13-24 02:10PM	Huntsman Inaugurates New Innovation Center in Tienen, Belgium (PR Newswire)
Jun-10-24 05:27PM	Huntsman Corporation (NYSE:HUN) Upgraded by JP Morgan (Insider Monkey)
Jun-06-24 09:18AM	Powering Big Tech: Huntsman Corp. CEO on the looming energy crisis for Silicon Valley (CNBC TV)
May-30-24 06:53AM	Why You Should Retain Huntsman (HUN) Stock in Your Portfolio (Zacks)
May-21-24 12:39PM	Huntsman Publishes 2023 Sustainability Report (PR Newswire)
May-09-24 04:00PM	Huntsman Announces Second Quarter 2024 Common Dividend (PR Newswire)
May-07-24 08:42AM	Huntsman's (HUN) Q1 Earnings Beat Estimates, Revenues Miss (Zacks)
May-04-24 09:36AM	Huntsman Corporation (NYSE:HUN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Huntsman Corp (HUN) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and ... (GuruFocus.com)
12:56AM	Q1 2024 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
May-02-24 08:30PM	Huntsman (HUN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:01PM	Huntsman Corp (HUN) Faces Challenges in Q1 2024, Misses Analyst Revenue and Earnings Estimates (GuruFocus.com)
05:09PM	Huntsman: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Huntsman Announces First Quarter 2024 Earnings (PR Newswire)
Apr-25-24 01:30PM	Huntsman Scholarship Program Awards 19 Spring ISD Students (PR Newswire)
10:01AM	Earnings Preview: Huntsman (HUN) Q1 Earnings Expected to Decline (Zacks)
Apr-08-24 08:16AM	Here's Why You Should Hold Onto Huntsman (HUN) Stock For Now (Zacks)
Apr-03-24 11:30AM	Huntsman To Donate $500,000 Over Next Five Years to Montgomery County Food Bank to Help Feed Additional 5,000 Households Per Month (PR Newswire)
Apr-01-24 07:38PM	Huntsman to Discuss First Quarter 2024 Results on May 3, 2024 (PR Newswire)
12:53PM	Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 11:30AM	Why Is Huntsman (HUN) Down 2.3% Since Last Earnings Report? (Zacks)
Mar-10-24 02:01PM	18 Highest Paying Countries for Chemical Engineers (Insider Monkey)
Feb-23-24 10:00AM	Huntsman Corporation (NYSE:HUN) Q4 2023 Earnings Call Transcript (Insider Monkey)
03:21AM	Q4 2023 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 07:19AM	Huntsman's (HUN) Q4 Earnings Miss Estimates, Revenues Beat (Zacks) +6.29%
Feb-21-24 05:08PM	Huntsman: Q4 Earnings Snapshot (Associated Press Finance)
04:55PM	Huntsman Corp (HUN) Reports Q4 2023 Earnings: Challenges Persist Amid Lower Revenues and Net Loss (GuruFocus.com)
04:45PM	Huntsman Announces Fourth Quarter 2023 Earnings (PR Newswire)
04:44PM	Huntsman Announces 5% Increase in First Quarter 2024 Common Dividend and 2024 Annual Meeting of Stockholders (PR Newswire)
Feb-15-24 09:15AM	Countdown to Huntsman (HUN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-14-24 10:00AM	Analysts Estimate Huntsman (HUN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-31-24 08:17AM	3 Sorry Materials Stocks to Sell in January 2024 (InvestorPlace)
Jan-26-24 04:00AM	Bear of the Day: Huntsman (HUN) (Zacks)
Jan-23-24 08:17AM	Here's Why You Should Hold Onto Huntsman (HUN) Stock For Now (Zacks)
Jan-19-24 07:00AM	Huntsman Updates Fourth Quarter 2023 Outlook; To Discuss Fourth Quarter 2023 Results on February 22, 2024; Results to be Released After Market Close on February 21, 2024 (PR Newswire)
Nov-30-23 11:31AM	Why Is Huntsman (HUN) Up 6.7% Since Last Earnings Report? (Zacks)
Nov-02-23 08:04PM	Huntsman Announces Fourth Quarter 2023 Common Dividend (PR Newswire)
07:47PM	Huntsman Corporation (NYSE:HUN) Q3 2023 Earnings Call Transcript (Insider Monkey)
05:01AM	Q3 2023 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:14AM	Huntsman's (HUN) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-31-23 06:06PM	Huntsman Corp (HUN) Reports Q3 2023 Earnings: Revenues Down 25% YoY, Net Income Drops to Zero (GuruFocus.com)
04:15PM	Huntsman Announces Third Quarter 2023 Earnings (PR Newswire)
Oct-24-23 10:00AM	Analysts Estimate Huntsman (HUN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-23-23 07:30AM	Want $1,000 in Passive Income? Invest $5,000 in These 3 Dividend Stocks and Wait 4 Years (Motley Fool)
Oct-18-23 09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
Oct-03-23 01:00PM	Huntsman to Discuss Third Quarter 2023 Results on November 1, 2023; Results to be Released After Market Close on October 31, 2023 (PR Newswire)
Sep-27-23 10:54AM	Huntsman (HUN) to Produce MIRALON Materials at New Plant (Zacks)
Sep-26-23 05:45PM	Huntsman starts construction on turquoise hydrogen and carbon nanotube production plant (American City Business Journals)
05:45PM	Hunstman starts construction on turquoise hydrogen and carbon nanotube production plant (American City Business Journals)
09:00AM	Construction Underway on Huntsman's 30-Ton Pilot Plant for MIRALON® Carbon Nanotube Materials (PR Newswire)
07:46AM	Huntsman (HUN) Unveils Technology Portal to Foster Collaboration (Zacks)
Sep-25-23 09:00AM	Huntsman Launches Technology Portal to Foster Innovation & Manufacturing-Driven Collaborations (PR Newswire)
Sep-19-23 09:27AM	Here's Why You Should Hold On to Huntsman (HUN) Stock For Now (Zacks)
Sep-12-23 12:40PM	Huntsman: Here's Why the Cards Are Stacked Against It (TheStreet.com)
12:20PM	Huntsman (HUN) Gains on Downstream Expansion, Acquisitions (Zacks)
Aug-15-23 09:16AM	Cabot (CBT) Joins US Energy Department's Better Plants Program (Zacks)
Aug-10-23 10:23AM	Has Huntsman Corporation's (NYSE:HUN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? (Simply Wall St.)
Aug-02-23 04:05PM	Huntsman Announces Third Quarter 2023 Common Dividend (PR Newswire)
10:22AM	Huntsman (HUN) Q2 Earnings and Revenues Miss Estimates (Zacks)
02:26AM	Q2 2023 Huntsman Corp Earnings Call (Thomson Reuters StreetEvents)
Jul-31-23 07:12PM	Huntsman: Q2 Earnings Snapshot (AP Finance)

Huntsman Corp. engages in the manufacturing of differentiated organic chemical products. It operates through the following segments: Polyurethanes, Performance Products, and Advanced Materials. The Polyurethanes segment manufactures and markets polyurethane chemicals, including MDI products, PO, polyols, PG, TPU, aniline, and MTBE. The Performance Products segment produces and sells amines, surfactants, LAB, and maleic anhydride to a variety of consumer and industrial end markets. The Advanced Materials segment provides basic liquid and solid epoxy resins, specialty resin compounds, cross linking, matting and curing agents, epoxy, acrylic, and polyurethane based polymer products. The company was founded by Jon Meade Huntsman Sr. in 1970 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beckerle Mary C	Director	Nov 06 '24	Sale	21.42	20,201	432,726	0	Nov 08 04:07 PM
Beckerle Mary C	Director	Nov 06 '24	Proposed Sale	21.42	20,201	432,730		Nov 06 02:22 PM
Lister Philip M.	Exec VP & CFO	Aug 21 '24	Option Exercise	21.01	6,305	132,468	118,895	Aug 23 04:07 PM
STRYKER DAVID M	Exec VP, GC and Sec	Aug 12 '24	Buy	20.11	2,500	50,273	424,579	Aug 13 04:10 PM

EXEL

Exelixis Inc

HUN

Huntsman Corp

Upgrade your FINVIZ experience